title: High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.
abstract: In order to compare oral and high-dose iv corticosteroid therapy for Graves' disease, 25 patients with Graves' ophthalmopathy were treated with two weekly iv injections of 1 g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks, and were compared to a group of 26 patients treated with oral prednisone at a dose of 60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months. The efficacy of treatment was evaluated using the ophthalmopathy index score. Patients were followed at 3, 6, 12 months, and afterwards yearly. All patients showed a significant improvement in signs and symptoms of orbital inflammation and a slight improvement in proptosis and diplopia. Relevant side-effects were reported from patients receiving oral therapy, but no significant side-effects were observed in patients treated with high iv doses; a few cases presented with gastric pain (highly sensitive to aluminium oxide or ranitidine), while most of the patients referred to cutaneous rashes and a metal taste that disappeared some hours after the infusion. Improvements observed after treatment have been stable in both groups. In conclusion, in addition to a lower incidence of side-effects compared to the classic oral therapy, the high-dose iv steroid therapy provides efficient and stable improvement in Graves' ophthalmopathy.
authors: Chair of Endocrinology, University of Naples Federico II, Napoli, Italy.
authors: P E
authors: PE
authors: Macchia
authors: M
authors: M
authors: Bagattini
authors: G
authors: G
authors: Lupoli
authors: M
authors: M
authors: Vitale
authors: G
authors: G
authors: Vitale
authors: G
authors: G
authors: Fenzi
mesh_terms: D015746:Abdominal Pain; D000328:Adult; D004890:Erythema / Q000139:chemically induced; D005094:Exophthalmos / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000627:therapeutic use; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D011241:Prednisone; D008775:Methylprednisolone